Bausch Health (BHC) Q2 2026 Earnings Call Transcript
Bausch Health (NYSE:BHC) reported Q2 2026 results excluding Bausch + Lomb: revenue $1.458B (+16%), adjusted EBITDA $865M (+28%), margin 59.3% (+530 bps), and adjusted operating cash flow $471M. Net debt fell to $13.7B. Full-year 2026 guidance was raised. Headwinds include Aplenzin LOE and CMS rebate impacts.
How this was made
The 30-second read
Why it matters
Management raised 2026 revenue, adjusted EBITDA, and cash flow guidance, while explicitly quantifying multiple 2H 2026 headwinds (inventory, rebates, and loss of exclusivity) that could affect margin trajectory and near-term earnings quality.
Market read
Traders can update 2026 earnings models using the raised guidance and the disclosed 2H 2026 headwinds, especially the CMS rebate timing and Aplenzin exclusivity loss.
What to watch
The call stresses gross-to-net accrual changes and CMS rebate timing (starting Jan 1, 2027), which can create accounting-driven volatility beyond cash flow optics.
Background
This is a Q2 2026 earnings call transcript for Bausch Health, with segment performance and full-year guidance updates.
Ticker impact
Bausch Health raised full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, while flagging 2H 2026 headwinds from Aplenzin LOE and CMS rebates.
Near-term bias positive on guidance raises, with potential pullback risk as investors model the 2H 2026 rebate and LOE headwinds.
The article provides specific guidance increases and quantified headwinds ($150M inventory headwind, $50M Aplenzin LOE, $75M Medicaid/340B erosion, and ~ $90M Q4 expense for CMS rebates), which should drive revisions to 2026 earnings expectations.
Market effects
Signals continued operating leverage in specialty pharma, but highlights how CMS rebate mechanics and LOE events can quickly swing gross-to-net and margins.
Solta Medical growth and China distribution integration are emphasized, supporting investor focus on international aesthetics and distribution execution.
International growth (Latin America, EMEA) and segment mix shifts may influence broader sentiment toward diversified pharma roll-ups.
Counterpoint
The guidance raise may be partially offset by later-year rebate and exclusivity impacts, so upside could be front-loaded while 2H 2026 results disappoint.
Key entities
- companyBausch Health Companies Inc.
Raised full-year 2026 guidance and outlined quantified 2H 2026 headwinds tied to Aplenzin LOE and CMS rebate-driven gross-to-net pressure.
- executiveThomas Appio
CEO highlighted performance consistency and openness to business development in new therapeutic areas using commercial AI engines.
- executiveJean-Jacques Charhon
CFO quantified guidance raises and near-term expense/rebate impacts, including an estimated ~$90M Q4 expense for CMS rebate increases.
